Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

Similar articles for PubMed (Select 23373009)

1.

MYCN and the epigenome.

He S, Liu Z, Oh DY, Thiele CJ.

Front Oncol. 2013 Jan 25;3:1. doi: 10.3389/fonc.2013.00001. eCollection 2013.

2.

Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.

Ochiai H, Takenobu H, Nakagawa A, Yamaguchi Y, Kimura M, Ohira M, Okimoto Y, Fujimura Y, Koseki H, Kohno Y, Nakagawara A, Kamijo T.

Oncogene. 2010 May 6;29(18):2681-90. doi: 10.1038/onc.2010.22. Epub 2010 Mar 1.

PMID:
20190806
3.

Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.

Manohar CF, Salwen HR, Brodeur GM, Cohn SL.

Genes Chromosomes Cancer. 1995 Nov;14(3):196-203.

PMID:
8589036
4.

Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.

Cetinkaya C, Hultquist A, Su Y, Wu S, Bahram F, Påhlman S, Guzhova I, Larsson LG.

Mol Cancer Ther. 2007 Oct;6(10):2634-41.

6.

The MYCN oncogene and differentiation in neuroblastoma.

Westermark UK, Wilhelm M, Frenzel A, Henriksson MA.

Semin Cancer Biol. 2011 Oct;21(4):256-66. doi: 10.1016/j.semcancer.2011.08.001. Epub 2011 Aug 9. Review.

PMID:
21849159
7.

Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.

Woo CW, Tan F, Cassano H, Lee J, Lee KC, Thiele CJ.

Pediatr Blood Cancer. 2008 Feb;50(2):208-12.

PMID:
17420990
8.

Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.

Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H, Maris JM, Prendergast GC, Hogarty MD.

Clin Cancer Res. 2003 Aug 15;9(9):3345-55.

9.

Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma.

Chen ST, Jeng YM, Chang CC, Chang HH, Huang MC, Juan HF, Hsu CH, Lee H, Liao YF, Lee YL, Hsu WM, Lai HS.

Cancer Sci. 2011 Dec;102(12):2191-8. doi: 10.1111/j.1349-7006.2011.02100.x. Epub 2011 Oct 17.

PMID:
21917080
10.

MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.

Lovén J, Zinin N, Wahlström T, Müller I, Brodin P, Fredlund E, Ribacke U, Pivarcsi A, Påhlman S, Henriksson M.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1553-8. doi: 10.1073/pnas.0913517107. Epub 2010 Jan 4.

11.

Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification.

Eggert A, Ho R, Ikegaki N, Liu XG, Brodeur GM.

Med Pediatr Oncol. 2000 Dec;35(6):623-7.

PMID:
11107132
13.

HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness.

Giannini G, Di Marcotullio L, Ristori E, Zani M, Crescenzi M, Scarpa S, Piaggio G, Vacca A, Peverali FA, Diana F, Screpanti I, Frati L, Gulino A.

Cancer Res. 1999 May 15;59(10):2484-92.

14.

Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.

Wagner LM, Burger RA, Guichard SM, Raimondi SC, Santana VM, Furman WL, Barnette P, Danks MK.

J Pediatr Hematol Oncol. 2006 Oct;28(10):635-41.

PMID:
17023822
15.

Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.

Henriksen JR, Haug BH, Buechner J, Tømte E, Løkke C, Flaegstad T, Einvik C.

BMC Dev Biol. 2011 Jan 3;11:1. doi: 10.1186/1471-213X-11-1.

16.

Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.

Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC.

J Natl Cancer Inst. 1995 Oct 4;87(19):1470-6.

PMID:
7674334
17.

MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin.

Gherardi S, Valli E, Erriquez D, Perini G.

Front Oncol. 2013 Mar 11;3:42. doi: 10.3389/fonc.2013.00042. eCollection 2013.

18.

MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.

Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM.

Cancer Res. 2007 Mar 15;67(6):2448-55.

19.

Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.

Nakagawa A, Matsuoka K, Okita H, Iwafuchi H, Hori H, Kumagai M.

Pediatr Dev Pathol. 2011 Mar-Apr;14(2):87-92. doi: 10.2350/08-12-0579.1. Epub 2011 Feb 2.

PMID:
21288077
20.

High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene.

Nair PN, McArdle L, Cornell J, Cohn SL, Stallings RL.

Cancer Genet Cytogenet. 2007 Apr 15;174(2):100-10.

PMID:
17452250
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk